Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Trimmed by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS cut its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 15.5% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 441,864 shares of the biopharmaceutical company's stock after selling 80,870 shares during the period. Kornitzer Capital Management Inc. KS owned approximately 0.35% of Halozyme Therapeutics worth $25,292,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HALO. GAMMA Investing LLC grew its stake in shares of Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 254 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in Halozyme Therapeutics during the 2nd quarter worth approximately $33,000. Whittier Trust Co. acquired a new position in shares of Halozyme Therapeutics in the 1st quarter valued at approximately $27,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $49,000. Finally, Toth Financial Advisory Corp purchased a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at approximately $57,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. The Goldman Sachs Group upped their price target on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a "neutral" rating in a report on Monday, July 22nd. HC Wainwright upped their target price on shares of Halozyme Therapeutics from $65.00 to $68.00 and gave the company a "buy" rating in a research note on Friday, November 1st. Benchmark reaffirmed a "buy" rating and set a $60.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Piper Sandler boosted their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a "neutral" rating in a report on Monday. Finally, Morgan Stanley increased their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an "overweight" rating in a report on Wednesday, August 7th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $61.11.

Insider Buying and Selling at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $62.03, for a total value of $620,300.00. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares of the company's stock, valued at $10,778,084.68. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, SVP Michael J. Labarre sold 10,000 shares of the company's stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $62.03, for a total value of $620,300.00. Following the completion of the sale, the senior vice president now owns 173,756 shares of the company's stock, valued at $10,778,084.68. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Matthew L. Posard sold 9,881 shares of the stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total transaction of $570,133.70. Following the completion of the transaction, the director now owns 69,874 shares of the company's stock, valued at $4,031,729.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 89,881 shares of company stock valued at $5,169,834 in the last ninety days. Company insiders own 2.70% of the company's stock.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO traded down $0.98 during mid-day trading on Thursday, hitting $59.65. The company had a trading volume of 1,061,025 shares, compared to its average volume of 1,288,829. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53. The stock has a market cap of $7.59 billion, a price-to-earnings ratio of 20.08, a PEG ratio of 0.53 and a beta of 1.29. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The firm's 50 day simple moving average is $56.75 and its two-hundred day simple moving average is $52.48.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a return on equity of 179.82% and a net margin of 41.43%. The company had revenue of $231.40 million for the quarter, compared to analysts' expectations of $204.94 million. During the same period last year, the business posted $0.68 earnings per share. The firm's quarterly revenue was up 4.7% compared to the same quarter last year. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 3.84 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.